Development of antibody resistance in emerging mutar for COVIDâ€19 vaccines

Reviews in Medical Virology 32, e2346

DOI: 10.1002/rmv.2346

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. Reviews in Medical Virology, 2022, 32, e2346.	8.3	16
2	An Effective Platform for SARS-CoV-2 Prevention by Combining Neutralization and RNAi Technology. Chinese Journal of Polymer Science (English Edition), 0, , .	3.8	O
3	An Engineered IgG–VHH Bispecific Antibody against SARSâ€CoVâ€⊋ and Its Variants. Small Methods, 2022, 6, .	8.6	4
5	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. Journal of Biomedical Research, 2023, 37, 166.	1.6	1
6	Efficacy of COVID-19 vaccination in organized group: results of a prospective study. Jurnal Infektologii, 2023, 14, 35-40.	0.3	1
7	Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry. PLoS Pathogens, 2023, 19, e1011131.	4.7	9
8	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. Current Pharmaceutical Biotechnology, 2023, 24, .	1.6	0
9	Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Journal of Virology, 2023, 97, .	3.4	1
10	Re-Emerging COVID-19: Controversy of Its Zoonotic Origin, Risks of Severity of Reinfection and Management. International Journal of General Medicine, 0, Volume 16, 4307-4319.	1.8	0
11	Aggregation-induced emission: recent applications in infectious diseases. Science China Chemistry, 2023, 66, 2986-3005.	8.2	2
12	Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVIDâ€19. Reviews in Medical Virology, 2024, 34, .	8.3	0
13	Analysis of SARS-CoV-2 genome evolutionary patterns. Microbiology Spectrum, 2024, 12, .	3.0	O
14	COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. Cureus, 2024, , .	0.5	2
15	Molecular, Immunological, and Clinical Characterization of SARS-CoV-2 Infection in Breakthrough-Infected Healthcare Workers During the Last Wave of The Pandemic in Shiraz, Iran. Jundishapur Journal of Microbiology, 2024, 16, .	0.5	0
16	Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis. World Journal of Virology, $0,13,13$	2.9	0